Komori
Medipal Holdings (7459) · RiskWorsenedLatest Other Disclosures (2026-09-24): "Advanced"

Surging Personnel and Logistics Costs Due to Labor Shortages

First written in FY2020-Q1. 7 of 13 entries say "Worsened", first in FY2022. Latest entry: 2026-09-24.

13entries
8years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMitigatedFY2020RestatedFY2021WorsenedFY2022 – FY20262019: 220192020: 220202021: 120212022: 220222023: 020232024: 120242025: 120252026: 42026
Same theme, other companies
Profit pressure from higher material, packing and freight, and labor costsA theme 142 companies write about · 145 as a headwind · 0 as a tailwind

Medipal Holdings moved to the "Worse" side of this theme in 2022, 1 year after the typical company in this theme (2021).

The whole theme swung hardest in 2022: 64 of 102 companies on the "Worse" side.

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 142 companies compared. The sentences above are computed from all 142.
Full recordFilings, disclosures and news, newest first
  1. 2026-09-24AdvancedOther Disclosures

    「2024年3月には、この技術を製造・物流現場へ広く提供することを目的として、両社は技術提携し、汎用モデルの製品化と販売に向けた取り組みを開始しました。今回の受賞は、両社がそれぞれの強みを持ち寄り、物流現場の課題解決に取り組んできた成果の一つと捉えています。」

    PALTACとオークラ輸送機が共同開発した段ボールケース開梱装置「REO」について、第30回日本MH大賞・優秀賞の受賞を契機に、製品化・販売および人手不足対策、省人化・自動化に向けた取組みを具体化した。
  2. FY2026WorsenedAnnual report

    「Selling, general and administrative expenses increased by ¥7,655 million, or 3.8%, from the previous fiscal year to ¥207,804 million, mainly due to higher business investment expenses in the wholesale business for prescription pharmaceuticals and other products, as well as higher personnel costs per employee resulting from investment in human resources and wage increases in the wholesale businesses for cosmetics and daily necessities and for over-the-counter pharmaceuticals.」

    Investment in personnel, higher unit labour costs resulting from wage increases, and higher business investment expenses and other costs were reflected in increased selling, general and administrative expenses.
  3. FY2026-H1WorsenedAnnual report

    「Selling, general and administrative expenses increased by ¥5,917 million, or 6.0%, due to higher business investment expenses and other costs in the prescription pharmaceuticals and other wholesale business, as well as increased investment in personnel and higher logistics costs in the cosmetics, daily necessities and OTC pharmaceuticals wholesale businesses.」

    Selling, general and administrative expenses increased 6.0% year on year due to increased investment in personnel, higher logistics costs and higher business investment expenses and other costs in the prescription pharmaceuticals and other wholesale business. Existing risks related to labour shortages and soaring logistics costs appeared in expenses.
  4. FY2025-H1WorsenedAnnual report

    「Selling, general and administrative expenses increased by ¥641 million due to higher logistics costs and increased investment in personnel, but the ratio to net sales improved by 0.04 percentage points through fixed-cost absorption, to 5.03%.」

    The company reported an increase in selling, general and administrative expenses due to higher logistics costs and increased investment in personnel. Meanwhile, the ratio to net sales improved through fixed-cost absorption.
  5. FY2023-Q1WorsenedAnnual report

    「Against this backdrop, our consolidated subsidiary PALTAC (Chuo-ku, Osaka) is steadily advancing initiatives to optimise and improve efficiency across the entire supply chain through collaboration and cooperation with relevant stakeholders, including strengthening a "system for products to sell" through collaboration and cooperation with business partners, improving deliveries in anticipation of the imminent 2024 logistics problem and white logistics, and actively recruiting personnel to support medium- to long-term growth.」

    In addition to the existing risks related to labour shortages and rising logistics costs, the company identified the 2024 logistics problem as an "imminent" issue requiring action. It is responding through delivery improvements and recruitment of personnel.
  6. FY2022WorsenedAnnual report

    「Although we are promoting efficiency improvements through labour-saving measures at logistics centres and a review of delivery operations, pursuing work-style reform and working to improve and develop the working environment, further tightening of labour supply and demand and an inability to secure sufficient personnel could affect the performance and financial position of our group. A substantial increase in employee-related costs due to amendments to laws or systems, fluctuations in prices or other factors could also affect the performance and financial position of our group.」

    In addition to the risk of labour shortages, the company explicitly identified the risk of substantial increases in employee-related costs due to amendments to laws and systems or fluctuations in prices.
  7. FY2021RestatedAnnual report

    「Although we are promoting efficiency improvements through labour-saving measures at logistics centres and a review of delivery operations, pursuing work-style reform and working to improve and develop the working environment, further tightening of labour supply and demand and an inability to secure sufficient personnel could affect the performance and financial position of our group.」

    The company continues to address the risk of labour shortages through labour-saving measures at logistics centres, a review of delivery operations and work-style reform.
  8. FY2020MitigatedAnnual report

    「Although we are promoting labour-saving measures at logistics centres, pursuing work-style reform and working to improve and develop the working environment, further tightening of labour supply and demand and an inability to secure sufficient personnel could affect the performance and financial position of our group.」

    The company identified labour-saving measures at logistics centres and work-style reform as measures to address the risk of labour shortages, difficulty securing personnel and rising costs.
  9. FY2020-Q3RestatedAnnual report

    「Labour shortages, which could impede growth across the industry, have been accompanied by higher labour and logistics costs, and their impact has grown further in various areas.」

    The company continues to state that the impact of higher labour and logistics costs due to labour shortages has grown further.
  10. FY2020-Q2RestatedAnnual report

    「Meanwhile, labour shortages, which could impede growth across the industry, have been accompanied by higher labour and logistics costs, and their impact has grown further in various areas.」

    The company continues to state that the impact of higher labour and logistics costs due to labour shortages has grown further.
  11. FY2020-Q1First statedAnnual report

    「Labour shortages, which could impede growth across the industry, have been accompanied by higher labour and logistics costs, and their impact has grown further in various areas.」

    The company stated that labour shortages have been accompanied by higher labour and logistics costs, with the impact on the business expanding.
Moved together

"Impact of Drug Price Standard Revisions on Pharmaceutical Selling Price Ceilings and Business Performance" moved the same way as this thread, in the same document, in 4 of its 13 moves.

422222★123456
  1. ★This thread
  2. 1Impact of Drug Price Standard Revisions on Pharmaceutical Selling Price Ceilings and Business Performance4×
  3. 2Improving Profitability and Creating New Value under PALTAC’s Medium-Term Management Plan for the Fiscal Year Ending March 20272×
  4. 3Transforming Existing Businesses and Enhancing Corporate Value through the 2017 Medipal Medium-Term Vision2×
  5. 4Risk Management Framework Based on Rules, Training, Manuals and Internal Audit2×
  6. 5Risk of Failure to Recover Logistics and Business Development Investments and of Incurring Losses2×
  7. 6Guarantees of borrowings by two Sinopharm Group Beijing companies2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Medipal Holdings's next results are scheduled for 2026-11-05. Read the earnings preview It last moved in the Other Disclosures of 2026-09-24: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Surging Personnel and Logistics Costs Due to Labor Shortages | MEDIPAL HOLDINGS CORPORATION (7459) | Komori